Stockscreener 앱 받기
0.3192
5.95%
-0.0202
시간 외 거래:
.32
0.0008
+0.25%
전일 마감가:
$0.3394
열려 있는:
$0.34
하루 거래량:
708.31K
Relative Volume:
0.67
시가총액:
$3.09M
수익:
-
순이익/손실:
$-4.74M
주가수익비율:
-0.4929
EPS:
-0.6476
순현금흐름:
$-3.46M
1주 성능:
-22.67%
1개월 성능:
-23.98%
6개월 성능:
-57.10%
1년 성능:
-71.24%
1일 변동 폭
$0.302
$0.3499
1주일 범위
$0.302
$0.42
52주 변동 폭
$0.302
$1.50
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
명칭
Lipella Pharmaceuticals Inc
전화
412-901-0315
주소
400 N LEXINGTON ST, PITTSBURGH
Lipella Pharmaceuticals Inc 주식(LIPO)의 최신 뉴스
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewswire
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily
Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily
Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily
Recent Insider Activity Suggests Potential Gains for KE Holdings Inc ADR (BEKE) - Knox Daily
Lipella Pharmaceuticals Inc [LIPO] is -57.84% lower this YTD. Is it still time to buy? - The DBT News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Huge semiconductor deal has eyes on this tech co 👀 - RagingBull
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - GlobeNewswire
Interstitial Cystitis Market Size is Set for Rapid Growth as - openPR
Sky Quarry Announces Closing of Public Offering of $6.7 Million - The Manila Times
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Expion360 Inc’s latest rating changes from various analysts - Knox Daily
Insider Buying: Kaufman Jonathan H, Lipella Pharmaceuticals Inc [LIPO] insider invested 10,000 shares - Knox Daily
The time has not yet come to remove your chips from the table: Lipella Pharmaceuticals Inc (LIPO) - SETE News
Lipella Pharmaceuticals Inc Inc. (LIPO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - Morningstar
Lipella reports positive phase 2a trial results for OLP treatment - Investing.com
Lipella Pharmaceuticals Reports Encouraging Early - GlobeNewswire
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus - StockTitan
A year in review: Lipella Pharmaceuticals Inc (LIPO)’s performance in the last year - US Post News
Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex
Lipella stock soars 200% on Phase 2 study initiation - MSN
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Benzinga
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
John Deneen Collins Sells 85,126 Shares of LivePerson, Inc. (NASDAQ:LPSN) Stock - Defense World
Lepidico Wins Crucial Road Access Dispute - TipRanks
Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada
LivePerson CFO and COO sells over $89k in company stock - Investing.com
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News
Moody’s to withdraw Lippo Malls Indonesia Retail Trust’s credit ratings - The Edge Singapore
UK Government gets behind Lepidico’s process technologies - Mining.com.au
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Understanding the Risks of Investing in Lipella Pharmaceuticals Inc (LIPO) - Knox Daily
Stock Surge: Lipella Pharmaceuticals Inc (LIPO) Closes at 0.40, Marking a 6.96 Increase/Decrease - The Dwinnex
A closer look at LIPO’s price-to-free cash flow ratio - US Post News
Interstitial Cystitis Market Growth Anticipated by 2032 | Companies includes Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation - Barchart
Lipella Pharmaceuticals announces board election and reverse stock split - Investing.com
Lipella Pharmaceuticals Inc [LIPO] Investment Guide: What You Need to Know - Knox Daily
Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment - MSN
A Guide To The Risks Of Investing In Lipella Pharmaceuticals Inc (LIPO) - Knox Daily
LIPO’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Lipella Pharmaceuticals Inc (LIPO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):